相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data
Patricia A. H. Hamers et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Prognostic significance of postsurgery circulating tumorDNAin nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
Jeanne Tie et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
Jenny F. Seligmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2021)
Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis
Rathin Gosavi et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR plus /- MEK inhibitors
E. Elez et al.
ANNALS OF ONCOLOGY (2021)
MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)
F. Pietrantonio et al.
ANNALS OF ONCOLOGY (2021)
KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
J. Weiss et al.
ANNALS OF ONCOLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
Laura Masfarre et al.
CANCERS (2021)
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Javier Ros et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)
M. Karoui et al.
ANNALS OF SURGERY (2020)
Biomarker-guided therapy for colorectal cancer: strength in complexity
Anita Sveen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
R. Corcoran et al.
ANNALS OF ONCOLOGY (2020)
Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer
Y. Sunakawa et al.
ANNALS OF ONCOLOGY (2020)
ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
A. Grothey et al.
ANNALS OF ONCOLOGY (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
David Lau et al.
ESMO OPEN (2020)
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
C. Santos et al.
ANNALS OF ONCOLOGY (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Giulia Siravegna et al.
CLINICAL CANCER RESEARCH (2019)
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
Giacomo Bregni et al.
JAMA ONCOLOGY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Thomas Reinert et al.
JAMA ONCOLOGY (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
526PDTRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
Y Nakamura et al.
ANNALS OF ONCOLOGY (2019)
527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
J H Strickler et al.
ANNALS OF ONCOLOGY (2019)
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
N. Tarazona et al.
ANNALS OF ONCOLOGY (2019)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles et al.
NATURE MEDICINE (2019)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Jeanne Tie et al.
JAMA ONCOLOGY (2019)
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco et al.
CANCER RESEARCH (2019)
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Stergios Boussios et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
F. Pietrantonio et al.
ANNALS OF ONCOLOGY (2018)
Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3
Jeffrey S. Ross et al.
CANCER (2018)
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Carolyn Hutter et al.
CELL (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Jonathan M. Loree et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Jonathan M. Loree et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Jennifer Ma et al.
NATURE COMMUNICATIONS (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery
J. Arredondo et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M. J. M. van Geel et al.
CANCER DISCOVERY (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).
Frank A. Sinicrope et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer
H. M. Mohan et al.
EJSO (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons
Carlyn Rose C. Tan et al.
CURRENT COLORECTAL CANCER REPORTS (2016)
HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Kanwal Pratap Singh Raghav et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial
Anders Jakobsen et al.
ACTA ONCOLOGICA (2015)
Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
Laurent Creancier et al.
CANCER LETTERS (2015)
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy
Pauline Maby et al.
CANCER RESEARCH (2015)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2015)
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
C. Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review
Yanliang Li et al.
TUMOR BIOLOGY (2015)
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
Marta Schirripa et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Milestones of Lynch syndrome: 1895-2015
Henry T. Lynch et al.
NATURE REVIEWS CANCER (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Wilson I. Gonsalves et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The BRAF Oncoprotein Functions through the Transcriptional Repressor MAFG to Mediate the CpG Island Methylator Phenotype
Minggang Fang et al.
MOLECULAR CELL (2014)
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis
C. Clancy et al.
COLORECTAL DISEASE (2013)
Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer
Yuji Toiyama et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Tomoya Yokota
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial
U. K. Dion Morton et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation
Jeanne Tie et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Emma R. Cantwell-Dorris et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component
S Ogino et al.
MODERN PATHOLOGY (2006)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative versus postoperative chemoradiotherapy for rectal cancer
R Sauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium
JP Russell et al.
ONCOGENE (2000)
分享论文
